Our new finding indicated that the dynamic changes in the expression of VEGF-C may play important roles in the progression of NAFLD and targeting for VEGF-C might be one of the main mechanisms of PTFC treatment. Here, VEGFC is linked to metabolic dysfunction-associated steatotic liver disease.